Literature DB >> 17145622

Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases.

X Frank Zhao1, Ken H Young, Dale Frank, Ami Goradia, Michael P Glotzbecker, Wilbur Pan, Leslie S Kersun, Ann Leahey, John P Dormans, John K Choi.   

Abstract

Most primary bone lymphomas (PBLs) are diffuse large B-cell lymphomas (DLBCLs). Pediatric PBL-DLBCL has a favorable prognosis but remains poorly characterized. Herein, 10 such cases are detailed. They involved 11- to 20-year-old males with bone lesions that were often painful. They were diagnosed often after months to years of symptoms, suggesting an indolent disease. All were successfully treated with chemotherapy with or without radiotherapy (0.5- to 24-year followup). Biopsy revealed that the lymphomas were paratrabecular or diffuse and were medium- to large-sized with round to irregular nuclei, dispersed chromatin, indistinct to small nucleoli, and abundant cytoplasm. Other features included varying levels of necrosis, cytoplasmic retraction, and myeloid hyperplasia. All cases marked as mature B cells, and most were CD10+ (7/10). Typical centroblastic morphologic features with nucleoli were rare, multilobated nuclei were uncommon, and CD10 negativity did not predict poor prognosis, unlike in the adult PBL-DLBCL. These findings suggest that pediatric and adult PBL-DLBCLs are distinct entities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17145622     DOI: 10.1309/LRQVTE5NM8B9ANLY

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Primary sternum diffuse large B-cell lymphoma: A case report and review of the literature.

Authors:  Meng-Ying Tong; Xian Zhang; Zhe Yu; Xiu-Hua Sun; Shuang Li; Yang Zhang
Journal:  Oncol Lett       Date:  2015-04-16       Impact factor: 2.967

2.  ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine.

Authors:  Gabriela Abrego; Julio García; Bruce Gilbert; Scott Forseen; Michael Toscano
Journal:  J Radiol Case Rep       Date:  2016-09-30

3.  Primary Bone Lymphoma of Humerus Diagnosed by FNAC- A Rare Case Report.

Authors:  H L Kishan Prasad; K Jayaprakash Shetty; Lawrence Mathias; Y Sunil Kumar; Harish S Permi; Chandrika Rao
Journal:  Indian J Surg Oncol       Date:  2013-07-17

4.  Imaging of primary pediatric lymphoma of bone.

Authors:  Kathryn S Milks; Thomas W McLean; Evelyn Y Anthony
Journal:  Pediatr Radiol       Date:  2016-04-04

Review 5.  Multifocal bone and bone marrow lesions in children - MRI findings.

Authors:  Maria Raissaki; Stelios Demetriou; Konstantinos Spanakis; Christos Skiadas; Nikolaos Katzilakis; Emmanouil G Velivassakis; Eftichia Stiakaki; Apostolos H Karantanas
Journal:  Pediatr Radiol       Date:  2016-12-21

6.  Bulky primary tibia mantle cell lymphoma achieved complete remission with CHOP and DHAP plus rituximab: A case report.

Authors:  Si Chen; Meng Ye
Journal:  Oncol Lett       Date:  2018-08-29       Impact factor: 2.967

7.  A thirteen year old female with primary T-cell rich B-cell lymphoma of bone masquerading as chronic recurrent multifocal osteomyelitis.

Authors:  Saadiya A Haque; Aziza Shad; Metin Ozdemirli; Victoria K Shanmugam; Bhaskar Kallakury
Journal:  Pediatr Rep       Date:  2009-06-08

8.  False Negative 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Primary B-cell Lymphoma of the Bone.

Authors:  Matthieu Pelletier-Galarneau; Patrick Martineau; Raymond Lambert; Sophie Turpin
Journal:  World J Nucl Med       Date:  2017 Apr-Jun

9.  [Clinical features of 11 cases of primary bone lymphoma].

Authors:  Y J Li; Y F Li; J W Du; L H Dong; X Gao; G P Li; X D Wei; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

10.  A highly curable lymphoma occurs preferentially in the proximal tibia of young patients.

Authors:  M Kristina Subik; Megan Herr; Robert E Hutchison; Jennifer Kelly; Wakenda Tyler; Mihai Merzianu; W Richard Burack
Journal:  Mod Pathol       Date:  2014-04-18       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.